Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sarepta Therapeutics Inc (NASDAQ:SRPT)

23.35
Delayed Data
As of May 25
 +4.91 / +26.63%
Today’s Change
8.00
Today|||52-Week Range
41.97
-39.48%
Year-to-Date
Should Investors Be Excited About Sarepta's Delay?
May 25 / MotleyFool.com - Paid Partner Content
Here's Why Sarepta Therapeutics' Stock Is Surging Higher Today
May 25 / MotleyFool.com - Paid Partner Content
Why Computer Sciences, Sarepta Therapeutics, and Nimble Storage Jumped Today
May 25 / MotleyFool.com - Paid Partner Content
Here's Why Sarepta (SRPT) Stock Is Skyrocketing Today
May 25 / TheStreet.com - Paid Partner Content
Sarepta (SRPT) Stock Spikes After FDA Delayed Approval Decision
May 25 / TheStreet.com - Paid Partner Content
A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review
May 25 / TheStreet.com - Paid Partner Content
Why is Sarepta Therapeutics (SRPT) Stock Soaring 20% Today?
May 25 / Zacks.com - Paid Partner Content
Sarepta Therapeutics (SRPT) Stock Jumps on Possibility of New Drug Approval
May 24 / TheStreet.com - Paid Partner Content
Trending Tickers: SRPT, BABA, CSC, CHK, C
May 25 / TheStreet.com - Paid Partner Content
Forget Sarepta Therapeutics, This DMD Stock Could Be A Better Buy
May 19 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close18.44
Today’s open22.15
Day’s range20.83 - 23.72
Volume21,352,147
Average volume (3 months)5,117,317
Market cap$844.1M
Dividend yield--
Data as of 4:00pm ET, 05/25/2016

Growth & Valuation

Earnings growth (last year)-53.39%
Earnings growth (this year)+12.91%
Earnings growth (next 5 years)+0.37%
Revenue growth (last year)-87.16%
P/E ratioNM
Price/Sales1,302.11
Price/Book4.42

Competitors

 Today’s
change
Today’s
% change
LCILannett Company Inc+0.30+1.30%
RGENRepligen Corp+0.49+2.03%
MGNXMacroGenics Inc+0.90+3.84%
MACKMerrimack Pharmaceut...-0.21-3.03%
Data as of 4:01pm ET, 05/25/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$1.20
Annual revenue (last year)$1.3M
Annual profit (last year)-$220.0M
Net profit margin-17,560.26%

Profile

Sector
Health Technology
Industry
Biotechnology
Senior VP, Chief Executive &
Medical Officer
Edward M. Kaye
Head-Operations &
Vice President
Gavin T. Malenfant
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs